2023 World Conference on Lung Cancer (Posters)-P1.12. LP-184, a Tumor Site Activated Small Molecule Acylfulvene, Is Effective Preclinically in Subsets of Lung Cancer

P1.12. LP-184, a Tumor Site Activated Small Molecule Acylfulvene, Is Effective Preclinically in Subsets of Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

Lantern Pharma is developing a drug called LP-184 to target specific subsets of lung cancers. LP-184 is a DNA damaging agent that belongs to the acylfulvene class of small molecule therapeutics. It is transformed into its bioactive form by an enzyme called PTGR1. LP-184 has shown broad in vitro anti-tumor activity in lung cancer cell lines, regardless of mutation status.<br /><br />In preclinical studies, LP-184 demonstrated strong anti-tumor potency in patient-derived lung cancer models with homologous recombination deficiencies. It was also effective in a xenograft model of lung cancer with KEAP1/ STK11 mutations. LP-184 has been found to be more potent than the PARP inhibitor Olaparib in these models.<br /><br />The company plans to launch a Phase 1 clinical trial for LP-184 in the second half of 2023. The trial will enroll patients with advanced solid tumors, including lung cancers. LP-184 has the potential to treat and control brain metastases from primary solid tumors.<br /><br />The safety profile of LP-184 has been assessed in animal studies, and it has been found to be well tolerated. LP-184 has shown reversible hematologic toxicity, which is expected for alkylating anticancer agents.<br /><br />Based on analysis of patient data, lung cancers with PTGR1 overexpression and KEAP1 mutations are predicted to be responders to LP-184 therapy.<br /><br />Overall, the preclinical studies support the further development of LP-184 in lung cancers, both small cell and non-small cell types.

Asset Subtitle

Reginald Ewesuedo

Meta Tag

Speaker Reginald Ewesuedo

Topic Tumor Biology: Translational Biology - Translational Therapeutics

Keywords

Lantern Pharma

LP-184

lung cancers

DNA damaging agent

acylfulvene class

PTGR1

anti-tumor activity

preclinical studies

Phase 1 clinical trial

brain metastases